◈ PeptideAtlasCONNECTED KNOWLEDGE
THE PEPTIDE REFERENCE

Afamelanotide

Afamelanotide is the active ingredient in a prescription implant used for adults with erythropoietic protoporphyria. Melanotan I is a historical name for the molecule. The approved medical use is distinct from unapproved products marketed for cosmetic tanning.

Also known as Scenesse · Melanotan I · NDP-alpha-MSH

Approved medicine · see jurisdictionEstablished clinical evidenceSkin & aging
AI-assisted source review · 2026-10-272 cited sources2 min read

At a glance

Approved productScenesse implant
Clinical contextAdult EPP with phototoxicity
Historical aliasMelanotan I
Main targetMelanocortin-1 receptor
Different compoundMelanotan II

Overview

Erythropoietic protoporphyria, or EPP, can cause severe pain after light exposure and markedly restrict daily life. Afamelanotide was developed to increase the amount of light exposure patients can tolerate without pain. Its approved implant is administered within a specialist care framework. Afamelanotide and Melanotan I identify the same molecule, while the approved implant and unapproved tanning products have very different clinical and regulatory contexts. Approval of Scenesse does not mean that every vial or spray carrying a related name has the same composition, delivery, evidence, or quality. Melanotan II is a different molecule with its own evidence and safety concerns.

Supporting sources [1] [2]

How it works

Afamelanotide activates melanocortin-1 receptors and increases eumelanin production. The pigment response can improve light tolerance in EPP, where abnormal protoporphyrin accumulation makes light exposure painful. This mechanism does not correct the underlying enzyme defect and does not establish general protection against skin cancer. The relevant clinical endpoint is pain-free light exposure, not simply a darker skin color.

Supporting sources [1] [2]

What the randomized studies measured

Two placebo-controlled trials in Europe and the United States enrolled 74 and 94 patients, respectively. Afamelanotide increased pain-free time in direct sunlight and improved quality-of-life measures. The trial endpoints were tied to a rare, debilitating photosensitivity disorder. They do not establish benefit for people seeking a cosmetic tan or permission to abandon sun protection.

Supporting sources [2]

Pigment changes require follow-up

The label describes darkening of existing nevi and other pigmentation changes, with regular full-body skin examinations recommended. Implant-site reactions and nausea are additional considerations. A pigment-producing mechanism is therefore accompanied by a surveillance requirement, rather than being assumed harmless because it resembles a naturally occurring hormone pathway.

Supporting sources [1]

Keep the product context visible

FDA approval covers the Scenesse implant for its specific adult EPP indication. An online Melanotan I product is not automatically that approved medicine. The historical alias does not change the importance of the exact formulation, administration route, quality controls, and authorized medical use.

Supporting sources [1]

Reading this profile

Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic alpha-melanocyte-stimulating-hormone analog.

This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.

Sources & references

Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.

  1. FDA prescribing information: Scenesse (afamelanotide) ↗
    Regulatory source · Checked 2026-10-27
  2. Afamelanotide for erythropoietic protoporphyria: randomized trials ↗
    Clinical trial source · Checked 2026-10-27
CONTINUE EXPLORING

Related profiles

Acetyl hexapeptide-8 ↗Acetyl hexapeptide-8 is a topical cosmetic peptide commonly associated with Argireline. Small controlled studies suggest an effect on wrinkle appearance, but they do not establish equivalence to injected botulinum toxin. Delivery through intact skin and the finished formulation remain important limitations.Acetyl octapeptide-3 ↗Acetyl octapeptide-3, commonly associated with SNAP-8, is a cosmetic ingredient marketed for expression-line appearance. Direct evidence for the isolated ingredient is limited. Studies of multi-ingredient microneedle patches cannot establish the effect of ordinary topical SNAP-8 products on their own.Acetyl tetrapeptide-5 ↗Acetyl tetrapeptide-5 is a cosmetic ingredient associated with the original Eyeseryl eye-contour products. Independent evidence isolating its contribution to puffiness or dark circles is sparse. A study of an injected multi-component product cannot validate a topical cream or the peptide alone.Bremelanotide ↗Bremelanotide is a prescription melanocortin agonist approved in the United States for a defined form of low sexual desire in premenopausal women. PT-141 is its development name. Evidence supports that specific indication, with meaningful cardiovascular and tolerability limitations.Melanotan II ↗Melanotan II is an unapproved tanning research peptide with effects beyond skin pigment. Very small early human studies reported nausea, fatigue, and sexual effects. Case reports and regulator warnings raise additional concerns, while long-term safety and product quality remain unresolved.Setmelanotide ↗Setmelanotide targets a central appetite pathway in specific rare forms of obesity. Current U.S. approval includes acquired hypothalamic obesity and defined syndromic or genetic conditions, with different minimum ages. It is not approved for ordinary polygenic obesity.